Quick and painless for the patient, VivoSight scans allow accurate diagnosis and more informed treatment decisions
VivoSight is designed with the patient in mind. A quick and painless scan of suspicious lesions provides dermatologists with actionable information to make a more accurate diagnosis. Clinical research has shown the ability for VivoSight to identify skin cancer at an early, more treatable stage.
VivoSight is used for non-melanoma skin cancer (NMSC) diagnosis, treatment selection and treatment monitoring. Because the scan images are accurate and immediately available, the need for a biopsy is often eliminated. For patients, this means reducing unnecessary scarring and removing the worrisome wait for results. The speed of image acquisition means that multiple lesions can be assessed quickly in areas of the skin where multiple biopsies would not be feasible.
Basal cell carcinoma, actinic keratosis (AK) and squamous cell carcinoma (SCC) – Kurzen, Prof. (2015). Hautsache Richtig Lesen. Der Privatarzt – Dermatologie, 5(2), 8-10.
VivoSight gives dermatologists the opportunity to make better-informed treatment choices and monitor the effectiveness of therapy over time. Identifying lesions suitable for topical drug therapy and monitoring its effectiveness, for example, is standard practice for many users. Using VivoSight for pre- and peri-operative assessment of tumour margins can help to optimise tumour excision and reduce post-operative scarring.